Treatment of chronic spontaneous urticaria with an inadequate response to H<inf>1</inf>-antihistamines: An expert opinion

Christian Vestergaard, Elias Toubi, Marcus Maurer, Massimo Triggiani, Barbara Ballmer-Weber, Alexander Marsland, Marta Ferrer, André Knulst, Ana Giménez-Arnau

    Research output: Contribution to journalReview articleResearchpeer-review

    33 Citations (Scopus)


    © 2017 John Libbey Eurotext. Chronic spontaneous urticaria (CSU) is characterized by the sudden, continuous or intermittent appearance of pruritic wheals (hives), angioedema, or both for six weeks or more, with no known specific trigger. The international EAACI/GA2LEN/EDF/WAO urticaria guideline advises standard-dose, second-generation H1-antihistamines as first-line therapy. However, H1-antihistamine treatment leads to absence of symptoms in fewer than 50% of patients. Updosing of second-generation H1-antihistamines (up to fourfold) as recommended by the EAACI/GA2LEN/EDF/WAO urticaria guideline as second-line therapy, can improve response, but many patients remain symptomatic. Definitions of response are often subjective and a consensus is needed regarding appropriate treatment targets. There is also an unmet need for biomarkers to assess CSU severity and activity and to predict treatment response. The EAACI/GA2LEN/EDF/WAO urticaria guideline recommends add-on omalizumab, ciclosporin A (CsA), or montelukast third-line treatment in patients with an inadequate response to high-dose H1-antihistamines. Omalizumab is currently the only licensed systemic biologic for use in CSU. Both omalizumab and CsA are effective third-line CSU treatments; montelukast appears to have lower efficacy in this setting. Omalizumab carries a label warning for anaphylaxis, although no cases of anaphylaxis were reported in the phase III trials of omalizumab in CSU and it is generally well tolerated in patients with CSU. Omalizumab arguably has a better safety profile than CsA.
    Original languageEnglish
    Pages (from-to)10-19
    JournalEuropean Journal of Dermatology
    Issue number1
    Publication statusPublished - 1 Jan 2017


    • Chronic spontaneous urticarial
    • H -antihistamines 1
    • Omalizumab
    • Response
    • Treatment


    Dive into the research topics of 'Treatment of chronic spontaneous urticaria with an inadequate response to H<inf>1</inf>-antihistamines: An expert opinion'. Together they form a unique fingerprint.

    Cite this